Huakong Kangtai (01312) announced its 2023 annual results. The group recorded revenue of HK$809 million, a year-on-year decrease...
According to the Zhitong Finance App, Huakong Kangtai (01312) announced its 2023 annual results. The group recorded revenue of HK$809 million, a year-on-year decrease of 9.5%. Shareholders' losses were HK$28.43 million, a year-on-year decrease of 30.6%. Loss per share was HK0.52 cents.
The Group's pharmaceutical business revenue and gross profit decreased by about 16.0% and 10.5%, respectively. The main reasons are as follows: due to the adverse effects of the adjustment of health insurance policies in mainland China, sales of Tongfang Pharmaceutical's main products fell sharply; under weak macroeconomic conditions, Chongqing Leisure sales declined as customer demand declined; Shaanxi Chenji Group sold it on May 9, 2023, and its revenue and gross profit as of the sale date were lower than last year.